ISHIHARA SANGYO KAISHA : ISK Announces Approval in Japan for BRENDA, the first therapeutic drug for Pancreatitis in Dogs.

FOR IMMEDIATE RELEASE

ISK Announces Approval in Japan for BRENDATM, the first therapeutic drug for Pancreatitis in Dogs.

•  JMAFF approves BRENDATM (fuzapladib sodium hydrate), the first drug of its kind for use by veterinarians in Japan to safely and effectively reduce the clinical signs associated with acute pancreatitis in dogs.

•  ISK is seeking FDA approval in the United States and has been assigned an INAD file number (Investigational New Animal Drug) for further clinical studies.

•  With ISK's advanced technology platform and leading-edge R&D in organic chemicals, the company plans to bring new innovative products to the US and other global markets.

OSAKA, Japan, September 28 2018 - Ishihara Sangyo Kaisha, Ltd. ("ISK") today announced that their first animal health product, BRENDATM (fuzapladib sodium hydrate) has been approved by the Japanese Ministry of Agriculture, Forestry and Fisheries (JMAFF) for use by veterinarians in Japan for the reduction of clinical signs associated with acute pancreatitis in dogs. BRENDA will be distributed in Japan by ZENOAQ (Nippon Zenyaku Kogyo Co., LTD.), one of the leading companies for the sales of animal pharmaceuticals in the Japanese market.

"Pancreatitis is often treated by addressing the symptoms. BRENDA has a critical drug efficacy for acute pancreatitis, allowing for a speedier recovery and decreased likelihood of long-term damage," explains Dr.Hiroshi Shikama, General Manager of the Research and Development Division at ISK Animal Health Headquarters.

BRENDA is ISK's first animal health pharmaceutical drug. It is being launched first in the Japanese market, with the intention of obtaining approval in other markets over time. With ISK's advanced technology platform and leading-edge R&D in organic chemicals, the company plans to become a strong player in the growing animal health industry by bringing new innovative products to the US and global markets. ISK is in the process of obtaining FDA approval in the United States.

About Ishihara Sangyo Kaisha, Ltd.

Ishihara Sangyo Kaisha, LTD. (ISK) is a chemical innovation company based in Japan and listed on Tokyo stock exchange market that develops a wide range of products in the areas of Agrochemical, Environmental Products, Functional Materials, Health Care Products and Titanium Dioxide Products. For more information on ISK visithttps://www.iskweb.co.jp/eng/.

MEDIA CONTACT:

Name: Hiro Watanabe, ISK Animal Health, LLC

Email:[e-mail]

Phone: [phone]

SOURCE URL:Link to ISK Website where the news release can be found

Forward-Looking Statements Disclaimer

Content in this release may contain forward-looking statements with respect to future results, performance and achievements that are subject to risk and uncertainties and reflect management's views and assumptions formed by available information. All statements other than statements of historical fact are statements that could be considered forward-looking statements. When used in this document, words such as "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "project" or "should" and similar expressions, as they relate to ISK, are intended to identify forward-looking statements.

Many factors could cause the actual results, performance or achievements of ISK to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements, including, among others, changes in general economic and business conditions, changes in currency exchange rates and interest rates, failure to obtain required governmental and regulatory approvals, introduction of competing products by other companies, lack of acceptance of new products or services by ISK's targeted customers, inability to meet efficiency and cost reduction objectives, changes in business strategy and various other factors, both referenced and not referenced in this release.